elbasvir-grazoprevir (Zepatier) -

elbasvir-grazoprevir (Zepatier)
Information type: Drug best practice guidance
Source: Scottish Medicines Consortium
Specialities: Infection and infectious diseases | Liver disorders
Summary
The SMC has accepted elbasvir-grazoprevir (Zepatier) for use within NHS Scotland for chronic hepatitis C in adults; the efficacy of Zepatier has not been demonstrated in genotypes 2, 3, 5 and 6 and is therefore not recommended in patients infected with these genotypes).
UKMi comment
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of elbasvir-grazoprevir (Zepatier).

Similarly, NICE has also approved use of elbasvir-grazoprevir (Zepatier) as an option for treating genotype 1 or 4 chronic hepatitis C in adults only if the company provides the drug at the same price or lower than that agreed with the Commercial Medicines Unit.
Related links: NICE guidance (October 2016)